[go: up one dir, main page]

DK131893D0 - 2-(substitueret methyl)-4-(substitueret ethoxy)-5-(lavere alkyl)-pyridinforbindelser, farmaceutisk praeparat, som indeholder saadanne samt anvendelse af en saadan forbindelse til fremstilling af et farmaceutisk praeparat - Google Patents

2-(substitueret methyl)-4-(substitueret ethoxy)-5-(lavere alkyl)-pyridinforbindelser, farmaceutisk praeparat, som indeholder saadanne samt anvendelse af en saadan forbindelse til fremstilling af et farmaceutisk praeparat

Info

Publication number
DK131893D0
DK131893D0 DK931318A DK131893A DK131893D0 DK 131893 D0 DK131893 D0 DK 131893D0 DK 931318 A DK931318 A DK 931318A DK 131893 A DK131893 A DK 131893A DK 131893 D0 DK131893 D0 DK 131893D0
Authority
DK
Denmark
Prior art keywords
group
stands
connection
substituted
alkyl
Prior art date
Application number
DK931318A
Other languages
English (en)
Other versions
DK131893A (da
Inventor
Shigeru Souda
Norihiro Ueda
Shuhei Miyazawa
Katsuya Tagami
Seiichiro Nomoto
Makoto Okita
Naoyuku Shimomura
Toshihiko Kaneko
Masatoshi Fujimoto
Manabu Murakami
Kiyoshi Oketani
Hideaki Fujisaki
Hisashi Shibata
Tsuneo Wakabayashi
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27283658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK131893(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of DK131893D0 publication Critical patent/DK131893D0/da
Publication of DK131893A publication Critical patent/DK131893A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK131893A 1986-11-13 1993-11-24 2-(Substitueret methyl)-4-(substitueret ethoxy)-5-(lavere alkyl)-pyridinforbindelser, farmaceutisk præparat, som indeholder sådanne samt anvendelse af en sådan forbindelse til fremstilling af et farmaceutisk præparat DK131893A (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP27053686 1986-11-13
JP2198987 1987-02-02
JP7778487 1987-03-31

Publications (2)

Publication Number Publication Date
DK131893D0 true DK131893D0 (da) 1993-11-24
DK131893A DK131893A (da) 1993-11-24

Family

ID=27283658

Family Applications (2)

Application Number Title Priority Date Filing Date
DK575887A DK171024B1 (da) 1986-11-13 1987-11-03 2-(4-(3-Methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl-1H-benzimidazol eller salte deraf, farmaceutisk præparat med et indhold deraf samt anvendelse deraf til fremstilling af et præparat til behandling eller forebyggelse af mavesår
DK131893A DK131893A (da) 1986-11-13 1993-11-24 2-(Substitueret methyl)-4-(substitueret ethoxy)-5-(lavere alkyl)-pyridinforbindelser, farmaceutisk præparat, som indeholder sådanne samt anvendelse af en sådan forbindelse til fremstilling af et farmaceutisk præparat

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK575887A DK171024B1 (da) 1986-11-13 1987-11-03 2-(4-(3-Methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl-1H-benzimidazol eller salte deraf, farmaceutisk præparat med et indhold deraf samt anvendelse deraf til fremstilling af et præparat til behandling eller forebyggelse af mavesår

Country Status (18)

Country Link
US (3) US5045552A (da)
EP (3) EP0654471B1 (da)
JP (1) JP2544567B2 (da)
KR (1) KR910003330B1 (da)
CN (1) CN1018923B (da)
AT (2) ATE163011T1 (da)
AU (1) AU594836B2 (da)
CA (1) CA1265138A (da)
DE (4) DE3752201T2 (da)
DK (2) DK171024B1 (da)
ES (3) ES2118457T3 (da)
FI (1) FI90544C (da)
HK (1) HK194296A (da)
HU (1) HU198475B (da)
LU (1) LU90396I2 (da)
NL (1) NL990015I2 (da)
NO (2) NO170932C (da)
NZ (1) NZ222488A (da)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62201884A (ja) * 1986-02-28 1987-09-05 Tokyo Tanabe Co Ltd ベンズイミダゾール誘導体及びその製造法
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
AT391693B (de) * 1988-11-15 1990-11-12 Cl Pharma Verfahren zur herstellung von 3-5-dimethyl-4methoxypyridinderivaten sowie neues zwischenprodukt hierfuer
US5294629A (en) * 1988-11-22 1994-03-15 Meiji Seika Kaisha, Ltd. Benzothiazole and benzimidazole derivatives and antiulcer agent containing the same
EG19302A (en) * 1988-12-22 1994-11-30 Haessle Ab Compound with gastric acid inhibitory effect and process for its preparation
SE8804629D0 (sv) * 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
US5049674A (en) * 1989-12-20 1991-09-17 Aktiebolaget Hassle Therapeutically active fluoro substituted benzimidazoles
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
ES2024357A6 (es) * 1990-12-05 1992-02-16 Genesis Para La Investigacion Procedimiento de obtencion de halohidrato de 2-halometil-3,5-dimetil-4-metoxipiri-dina.
NZ244301A (en) * 1991-09-20 1994-08-26 Merck & Co Inc Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds
US5504082A (en) * 1992-06-01 1996-04-02 Yoshitomi Pharmaceutical Industries, Ltd. Pyridine compound and pharmaceutical compostions
WO1995011897A1 (en) * 1993-10-29 1995-05-04 Yoshitomi Pharmaceutical Industries, Ltd. Pyridine compound and medicinal use thereof
DK0585722T3 (da) * 1992-08-21 1996-08-05 Eisai Co Ltd Benzimidazolderivater som antimikrobielt middel mod Campylobacter pylon
JPH08507054A (ja) * 1993-02-17 1996-07-30 ビイク グルデン ロンベルク ヒェーミッシェ ファブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング ヘリコバクターバクテリアに対抗するための置換されたヘテロアリールアルキルチオピリジン
WO1995001351A1 (de) * 1993-06-29 1995-01-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituierte arylthioalkylthiopyridine
TW280770B (da) 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
KR0142815B1 (ko) * 1994-12-02 1998-07-15 정도언 신규한 5-피롤릴-6-할로게노-2피리딜메틸설피닐벤즈이미다졸 유도체
KR0179401B1 (ko) * 1994-02-28 1999-03-20 송택선 신규한 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체
HRP960232A2 (en) * 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
KR970032861A (ko) * 1995-12-29 1997-07-22 김준웅 헬리코박터 피로리 제거용 약제 투여방법
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
AU6551198A (en) * 1997-05-30 1998-12-30 Dr. Reddy's Research Foundation Novel benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them
SI1003554T1 (en) 1997-07-25 2005-04-30 Altana Pharma Ag Proton pump inhibitor in therapeutic combination with antibacterial substances
ATE332133T1 (de) * 1997-10-14 2006-07-15 Eisai Co Ltd Pharmazeutische zusammensetzung enthaltend glyzin als stabilisator
US7230014B1 (en) 1997-10-14 2007-06-12 Eisai Co., Ltd. Pharmaceutical formulation comprising glycine as a stabilizer
US6861448B2 (en) 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
ATE271555T1 (de) 1998-01-14 2004-08-15 Uab Research Foundation Verfahren zur herstellung und screening von inhibitoren des bakteriellen nad synthetase enzyms, verbindungen daraus und methoden zur behandlung bakterieller und mikrobieller infektionen mit diesen inhibitoren
DE19815634A1 (de) * 1998-04-07 1999-10-14 Bayer Ag Verfahren zur Herstellung von 3-Methoxy-1-propanol
JP2002512263A (ja) * 1998-04-30 2002-04-23 セプラコール， インク． Ｓ−レイブプラゾール組成物及び方法
EP1073332A4 (en) * 1998-04-30 2005-06-15 Sepracor Inc R-RABEPRAZOLE COMPOSITIONS AND METHODS
AU4387799A (en) * 1998-06-26 2000-01-17 Russinsky Limited Pyridine building blocks as intermediates in the synthesis of pharmaceutically active compounds
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
PL346000A1 (en) 1998-08-10 2002-01-14 Partnership Of Michael E Garst Prodrugs of proton pump inhibitors
DE69930648T2 (de) 1998-08-12 2006-12-21 Altana Pharma Ag Orale darreichungsform für pyridin-2-ylmethylsulfinyl-1h-benzimidazole
DE19843413C1 (de) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
JP3926936B2 (ja) 1998-11-16 2007-06-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホキシド誘導体・アセトン錯体およびその製造法
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6174902B1 (en) 1999-04-28 2001-01-16 Sepracor Inc. R-rabeprazole compositions and methods
EP1616562A1 (en) 1999-06-07 2006-01-18 ALTANA Pharma AG Novel preparation and administration form comprising an acid-labile active compound
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
AU2001251083A1 (en) 2000-03-31 2001-10-15 Ortho-Mcneil Pharmaceutical, Inc. Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists
AU2001266988A1 (en) * 2000-06-19 2002-01-02 Eisai Co. Ltd. Novel methods using pyridine derivatives
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
EP1341528B1 (en) 2000-12-07 2012-01-18 Nycomed GmbH Rapidly disintegrating tablet comprising an acid-labile active ingredient
ES2375269T3 (es) 2000-12-07 2012-02-28 Nycomed Gmbh Preparado farmacéutico en forma de una pasta que comprende un ingrediente activo l�?bil ante los �?cidos.
AU2002234545A1 (en) 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Pharmaceutical preparation in the form of a suspension comprising an acid-labileactive ingredient
NL1018295C2 (nl) * 2001-06-15 2002-12-17 Dsm Nv Werkwijze voor de bereiding van 4-chloor-pyridine-n-oxiden.
US6884810B2 (en) 2001-09-18 2005-04-26 Zeria Pharmaceutical Co., Ltd. Benzimidazole derivatives
WO2003063927A2 (en) * 2001-11-16 2003-08-07 Eisai Co. Ltd Compositions and methods to treat gastrointestinal disorders
SE0104295D0 (sv) * 2001-12-18 2001-12-18 Astrazeneca Ab New process
AU2003224781A1 (en) * 2002-03-26 2003-10-13 Dr. Reddy's Laboratories Limited Crystalline forms of rabeprazole sodium
WO2003097011A1 (en) * 2002-05-17 2003-11-27 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
AU2003254282A1 (en) * 2002-08-01 2004-02-23 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
AT413538B (de) * 2002-10-01 2006-03-15 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von substituierten pyridin-n-oxid-verbindungen
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
ME00563A (en) 2002-12-06 2011-12-20 Process for preparing optically pure active compounds
BR0316702A (pt) 2002-12-06 2005-10-18 Altana Pharma Ag xprocesso para preparação de (s)-pantoprazol
US20060122233A1 (en) * 2002-12-16 2006-06-08 Yatendra Kumar Rabeprazole calcium
WO2004056804A2 (en) * 2002-12-19 2004-07-08 Teva Pharmaceutical Industries Ltd. Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
CN1723208A (zh) * 2003-01-07 2006-01-18 兰贝克赛实验室有限公司 咪唑衍生物的镁盐
US20040180935A1 (en) * 2003-02-28 2004-09-16 Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Inc. Crystalline form Z of rabeprazole sodium and process for preparation thereof
WO2004080961A2 (en) * 2003-03-12 2004-09-23 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous solids of pantoprazole and processes for their preparation
WO2004080487A1 (ja) * 2003-03-13 2004-09-23 Eisai Co. Ltd. 歯ぎしりの予防剤または治療剤
KR100714375B1 (ko) * 2003-03-24 2007-05-02 에자이 알앤드디 매니지먼트 가부시키가이샤 술폭시드 유도체 또는 그 염의 아몰퍼스의 제조방법
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
US7524837B2 (en) * 2003-05-12 2009-04-28 Janssen Pharmaceutica N.V. Benzotriazapinone salts and methods for using same
US7683177B2 (en) * 2003-06-10 2010-03-23 Teva Pharmaceutical Industries Ltd Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
JP2007521314A (ja) * 2003-07-15 2007-08-02 アラーガン、インコーポレイテッド プロトンポンプ阻害薬の異性体純粋なプロドラッグを製造するための方法
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
MXPA06002443A (es) * 2003-09-03 2006-08-31 Agi Therapeutics Ltd Formulaciones inhibidoras de la bomba de protones y metodos para preparar y utilizar tales formulaciones.
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
WO2005039640A1 (en) * 2003-10-03 2005-05-06 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs
WO2005077936A1 (en) 2004-02-11 2005-08-25 Ulkar Kimya Sanayii Ve Ticaret A.S. Pyridine benzimidazole sulfoxides with high purity
BRPI0507784A (pt) * 2004-02-18 2007-07-17 Allergan Inc métodos e composições para a administração de pró-fármacos de inibidores da bomba de prótons
AU2005216863A1 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Methods and compositions for the intravenous administration of compounds related to proton pump inhibitors
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
PT1746980E (pt) * 2004-05-07 2012-01-25 Nycomed Gmbh Forma de dosagem farmacêutica compreendendo granulados assim como o seu processo de fabrico
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2006003946A1 (ja) * 2004-06-30 2006-01-12 Eisai R & D Management Co., Ltd. ベンズイミダゾール誘導体塩沈殿物の製造方法
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
JP3921497B2 (ja) * 2004-08-06 2007-05-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンズイミダゾール誘導体とアミンとの塩およびその製造方法
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
WO2006024890A1 (en) * 2004-08-30 2006-03-09 Apollo International Limited Improved process for rabeprazole sodium in amorphous form
CN100364989C (zh) * 2004-09-30 2008-01-30 江苏豪森药业股份有限公司 拉唑类衍生物及其盐和用途
CA2603290A1 (en) * 2004-09-30 2006-04-06 Jiangsu Hansen Pharmaceutical Co., Ltd. Prazole derivatives and salts thereof and use of same
CN101107013A (zh) 2004-11-22 2008-01-16 阿纳迪斯有限公司 生物活性组合物
AU2006242782B2 (en) * 2005-02-21 2010-11-04 Cipla Limited New process for synthesis of proton pump inhibitors
JP2008534578A (ja) * 2005-03-30 2008-08-28 ルピン・リミテッド ラベプラゾールナトリウムの改良された製法
US7601737B2 (en) 2005-07-26 2009-10-13 Nycomed Gmbh Isotopically substituted proton pump inhibitors
GB0525710D0 (en) * 2005-12-17 2006-01-25 Pliva Hrvatska D O O An improved process for preparing of substituted 2-benzimidazolesulfoxide compounds
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP1818331A1 (en) 2006-02-14 2007-08-15 EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. Process for the preparation of 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole substantially free of sulfone impurity
ES2374730T3 (es) * 2006-03-10 2012-02-21 Arigen Pharmaceuticals, Inc. Nuevo derivado de piridina que tiene actividad contra helicobacter pylori.
CA2648280C (en) 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
KR100771655B1 (ko) * 2006-04-24 2007-10-30 주식회사 카이로제닉스 라베프라졸 및 그 중간체의 제조방법
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US7786309B2 (en) 2006-06-09 2010-08-31 Apotex Pharmachem Inc. Process for the preparation of esomeprazole and salts thereof
US7863330B2 (en) 2006-06-14 2011-01-04 Rottapharm S.P.A. Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
WO2008017020A2 (en) * 2006-08-03 2008-02-07 Dr. Reddy's Laboratories Limited Process for preparing proton pump inhibitors
US20100317689A1 (en) * 2006-09-19 2010-12-16 Garst Michael E Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
WO2008067037A2 (en) 2006-10-05 2008-06-05 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
JP5492417B2 (ja) * 2006-10-13 2014-05-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 胃酸分泌抑制作用を有するベンズイミダゾール化合物
CA2667682A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
RU2451682C2 (ru) 2006-12-18 2012-05-27 Ариджен Фармасьютикалз, Инк. ПРЕПАРАТ ПРОТИВ Helicobacter pylori, ИНГИБИРУЮЩИЙ СЕКРЕЦИЮ ЖЕЛУДОЧНОГО СОКА
ITMI20062449A1 (it) 2006-12-19 2008-06-20 Dipharma Spa Forma cristallina di rabeprazolo sodico
ZA200904573B (en) 2006-12-22 2010-09-29 Ironwood Pharmaceuticals Inc Compositions comprising bile acid sequestrants for treating esophageal disorders
US20100145057A1 (en) * 2007-03-15 2010-06-10 Sun Pharma Advanced Research Company Ltd. Novel prodrugs
EP2162449A4 (en) * 2007-05-25 2011-07-13 Hetero Drugs Ltd IMPROVED PROCESS FOR THE PREPARATION OF AMORPHOUS SODIUM RABEPRAZOLE
WO2008155780A2 (en) * 2007-06-21 2008-12-24 Matrix Laboratories Ltd Improved process for the preparation of pure rabeprazole
WO2009010937A1 (en) * 2007-07-17 2009-01-22 Ranbaxy Laboratories Limited Process for the preparation op pantoprazole sodium and pantoprazole sodium sesquihydrate
CN101497604B (zh) * 2008-01-30 2012-09-26 山东轩竹医药科技有限公司 含有被烷氧乙酰胺基氧基取代的吡啶的苯并咪唑衍生物
CN101497603B (zh) * 2008-01-30 2012-11-07 山东轩竹医药科技有限公司 含有被烷氧烷胺氧基取代的吡啶的苯并咪唑衍生物
SI22806A (sl) * 2008-06-23 2009-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Nove kristalinične oblike natrijevega rabeprazola
AU2010235726B2 (en) 2009-04-09 2012-01-19 Link Genomics, Inc. Pyridine thio derivative, and pharmaceutical composition which contains same and has anti-Helicobacter pylori action
WO2010134099A1 (en) 2009-05-21 2010-11-25 Cadila Healthcare Limited One pot process for preparing omeprazole and related compounds
WO2011004281A1 (en) 2009-07-09 2011-01-13 Alembic Limited A process for the preparation of amorphous form of rabeprazole sodium
CN102140099A (zh) 2010-02-02 2011-08-03 山东轩竹医药科技有限公司 新的吡啶衍生物
AU2011234001B2 (en) * 2010-03-31 2014-08-28 Sun Pharmaceutical Industries Limited Salts of dexlansoprazole and their preparation
CN102219777B (zh) * 2010-04-19 2013-06-05 江苏豪森药业股份有限公司 制备雷贝拉唑钠的方法
CN101805327B (zh) * 2010-04-29 2012-11-21 郝志艳 一种雷贝拉唑钠化合物及其制法
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
CN104114169A (zh) 2011-12-16 2014-10-22 阿托佩斯治疗有限公司 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物
WO2013108068A1 (en) 2012-01-21 2013-07-25 Jubilant Life Sciences Limited Process for the preparation of 2-pyridinylmethylsulfinyl benzimidazoles, their analogs and optically active enantiomers
WO2014091450A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Process for the preparation of rabeprazole
JP6716255B2 (ja) 2013-01-15 2020-07-01 アイロンウッド ファーマシューティカルズ，インコーポレーテッドＩｒｏｎｗｏｏｄ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 胆汁酸捕捉剤の胃内滞留型徐放性経口剤形
CN103073536B (zh) * 2013-01-17 2015-06-24 丽珠医药集团股份有限公司 一种艾普拉唑的制备方法
CN103709141A (zh) * 2013-10-14 2014-04-09 寿光富康制药有限公司 雷贝拉唑钠的晶型及无定形形式
CN104119315B (zh) * 2014-05-21 2016-03-02 丽珠医药集团股份有限公司 一种雷贝拉唑钠的制备方法
RU2554735C1 (ru) * 2014-08-20 2015-06-27 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция, содержащая рабепразол натрия, и способ ее получения
US20180015118A1 (en) 2015-02-03 2018-01-18 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN106083705A (zh) * 2016-06-14 2016-11-09 上药康丽（常州）药业有限公司 2‑羟甲基‑4‑（甲氧基丙氧基）‑3‑甲基吡啶盐酸盐的制备方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN106349220A (zh) * 2016-08-25 2017-01-25 岳阳正昊化学科技有限公司 一种右旋雷贝拉唑钠的纯化方法
US11253503B2 (en) 2016-09-24 2022-02-22 Washington University Inhibitors of SARM1 NADase activity and uses thereof
US12364721B2 (en) 2019-09-24 2025-07-22 Prolacta Bioscience, Inc. Compositions and methods for treatment of inflammatory and immune diseases
EP4598528A1 (en) 2022-10-04 2025-08-13 Arsenil Zabirnyk Inhibition of aortic valve calcification

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL66340A (en) * 1981-08-13 1986-08-31 Haessle Ab Pharmaceutical compositions comprising pyridylmethyl-thiobenzimidazole derivatives,certain such novel derivatives and their preparation
SE8300736D0 (sv) * 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
GB8417171D0 (en) * 1984-07-05 1984-08-08 Beecham Group Plc Compounds
SE8404065D0 (sv) * 1984-08-10 1984-08-10 Haessle Ab Novel biologically active compounds
DE3509333A1 (de) * 1985-03-15 1986-09-18 Hoechst Ag, 6230 Frankfurt Substituierte benzimidazolderivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung als magensaeuresekretionshemmer
JPH0674272B2 (ja) * 1986-11-13 1994-09-21 エーザイ株式会社 ピリジン誘導体及びそれを含有する潰瘍治療剤
DE4036908A1 (de) * 1990-11-20 1992-05-21 Ruetgers Pagid Ag Nutausbildung

Also Published As

Publication number Publication date
JPH05247035A (ja) 1993-09-24
NO2000006I1 (no) 2000-09-18
EP0268956A3 (en) 1990-07-25
HK194296A (en) 1996-11-01
KR880006229A (ko) 1988-07-22
HU198475B (en) 1989-10-30
NO170932B (no) 1992-09-21
FI874709L (fi) 1988-05-14
KR910003330B1 (ko) 1991-05-27
DK575887A (da) 1988-05-14
NL990015I1 (nl) 1999-08-02
US5045552A (en) 1991-09-03
US5998445A (en) 1999-12-07
NZ222488A (en) 1993-05-26
DE3752201D1 (de) 1998-08-13
DK131893A (da) 1993-11-24
CA1265138A (en) 1990-01-30
ES2118457T3 (es) 1998-09-16
ATE163011T1 (de) 1998-02-15
US5840910A (en) 1998-11-24
ES2061471T5 (es) 1998-07-16
FI874709A0 (fi) 1987-10-26
DE3752167T2 (de) 1998-06-25
ES2061471T3 (es) 1994-12-16
AU8113887A (en) 1988-05-19
EP0268956B2 (en) 1998-04-15
NO874477L (no) 1988-05-16
DE3789536T2 (de) 1994-08-18
DK575887D0 (da) 1987-11-03
DK171024B1 (da) 1996-04-22
EP0268956B1 (en) 1994-04-06
CN1018923B (zh) 1992-11-04
EP0654471A1 (en) 1995-05-24
DE3789536T3 (de) 1998-08-20
NL990015I2 (nl) 1999-09-01
NO170932C (no) 1992-12-30
EP0475456B1 (en) 1998-02-04
LU90396I2 (fr) 1999-07-07
JP2544567B2 (ja) 1996-10-16
DE19975035I2 (de) 2004-01-29
DE3752167D1 (de) 1998-03-12
EP0268956A2 (en) 1988-06-01
FI90544C (fi) 1994-02-25
DE3789536D1 (de) 1994-05-11
NO874477D0 (no) 1987-10-27
FI90544B (fi) 1993-11-15
CN87107777A (zh) 1988-06-01
DE3752201T2 (de) 1998-12-17
EP0654471B1 (en) 1998-07-08
ATE168111T1 (de) 1998-07-15
ES2112260T3 (es) 1998-04-01
AU594836B2 (en) 1990-03-15
EP0475456A1 (en) 1992-03-18
HUT45524A (en) 1988-07-28

Similar Documents

Publication Publication Date Title
DK131893D0 (da) 2-(substitueret methyl)-4-(substitueret ethoxy)-5-(lavere alkyl)-pyridinforbindelser, farmaceutisk praeparat, som indeholder saadanne samt anvendelse af en saadan forbindelse til fremstilling af et farmaceutisk praeparat
PT88410A (pt) Process for preparing thiazolidinedione derivatives
EP0097323A3 (en) 2-(4-pyridyl)-thiazole derivatives
AU5062996A (en) Novel pyridine compounds, processes for their preparation and the pharmaceutical compositions which contain them
ES474229A1 (es) Un procedimiento de preparacion de derivados de fenil-4-ami-no-2-tiazol
FI872930A0 (fi) Analogiamenetelmä ripulinvastaisten 4-(bentsoyyliamino)piperidiinibutaaniamidijohdannaisten valmistamiseksi
DK0485219T3 (da) Lægemidler til forebyggelse og behandling af kredsløbsorgansygdomme indeholdende spiro-3-heteroazolidinforbindelser
DK702788A (da) Thioformamidderivater og farmaceutisk acceptable salte deraf, deres fremstilling og anvendelse
GR3026762T3 (en) Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and a process for preparing the same

Legal Events

Date Code Title Description
A0 Application filed
ARF Application refused